Literature DB >> 17630404

Raised risk of Wilms tumour in patients with aniridia and submicroscopic WT1 deletion.

Veronica van Heyningen, Jan M N Hoovers, Jan de Kraker, John A Crolla.   

Abstract

OBJECTIVE: The aim of this study was to determine if there is a significant difference in the risk of developing Wilms tumour between patients with submicroscopic and those with visible deletions of the WT1 tumour suppressor gene.
METHODS: To determine which subjects had WT1 deletions, high-resolution chromosomal deletion analysis of the 11p13 region was carried out in 193 people with aniridia. The rationale for this was that aniridia is caused by loss of function of one copy of the PAX6 gene, and although most patients with aniridia have intragenic mutations, a proportion has deletions that also include the nearby WT1 gene. Fluorescence in situ hybridisation (FISH) analysis of patients with aniridia identifies people with WT1 deletions regardless of whether they have Wilms tumour, allowing the deletion size to be correlated with clinical outcome.
RESULTS: Wilms tumour was not observed in any case without a WT1 deletion. Of subjects in whom WT1 was deleted, 77% with submicroscopic deletions (detectable only by high-resolution FISH analysis) presented with Wilms tumour compared with 42.5% with visible deletions (detectable by microscopy). This difference was significant.
CONCLUSIONS: High-resolution deletion analysis is a useful tool for assessing the risk of Wilms tumour in neonates with aniridia. People with submicroscopic WT1 deletions have a significantly increased risk of Wilms tumour, and a high level of vigilance should be maintained in such cases.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17630404      PMCID: PMC2652818          DOI: 10.1136/jmg.2007.051318

Source DB:  PubMed          Journal:  J Med Genet        ISSN: 0022-2593            Impact factor:   6.318


  25 in total

Review 1.  Recent advances in Wilms tumor genetics.

Authors:  Jeffrey S Dome; Max J Coppes
Journal:  Curr Opin Pediatr       Date:  2002-02       Impact factor: 2.856

2.  WT1 is a key regulator of podocyte function: reduced expression levels cause crescentic glomerulonephritis and mesangial sclerosis.

Authors:  Jian-Kan Guo; Aswin L Menke; Marie-Claire Gubler; Alan R Clarke; David Harrison; Annette Hammes; Nicholas D Hastie; Andreas Schedl
Journal:  Hum Mol Genet       Date:  2002-03-15       Impact factor: 6.150

3.  Genetic mechanisms of tumor-specific loss of 11p DNA sequences in Wilms tumor.

Authors:  D D Dao; W T Schroeder; L Y Chao; H Kikuchi; L C Strong; V M Riccardi; S Pathak; W W Nichols; W H Lewis; G F Saunders
Journal:  Am J Hum Genet       Date:  1987-08       Impact factor: 11.025

Review 4.  WT1 and glomerular diseases.

Authors:  Patrick Niaudet; Marie-Claire Gubler
Journal:  Pediatr Nephrol       Date:  2006-08-23       Impact factor: 3.714

5.  Characteristics and outcomes of children with the Wilms tumor-Aniridia syndrome: a report from the National Wilms Tumor Study Group.

Authors:  Norman E Breslow; Robin Norris; Patricia A Norkool; Tammy Kang; J Bruce Beckwith; Elizabeth J Perlman; Michael L Ritchey; Daniel M Green; Kim E Nichols
Journal:  J Clin Oncol       Date:  2003-12-15       Impact factor: 44.544

6.  Aniridia. A review.

Authors:  L B Nelson; G L Spaeth; T S Nowinski; C E Margo; L Jackson
Journal:  Surv Ophthalmol       Date:  1984 May-Jun       Impact factor: 6.048

7.  Twenty-four new cases of WT1 germline mutations and review of the literature: genotype/phenotype correlations for Wilms tumor development.

Authors:  Brigitte Royer-Pokora; Manfred Beier; Markus Henzler; Rita Alam; Valérie Schumacher; Angela Weirich; Vicki Huff
Journal:  Am J Med Genet A       Date:  2004-06-15       Impact factor: 2.802

8.  PAX6 haploinsufficiency causes cerebral malformation and olfactory dysfunction in humans.

Authors:  S M Sisodiya; S L Free; K A Williamson; T N Mitchell; C Willis; J M Stevens; B E Kendall; S D Shorvon; I M Hanson; A T Moore; V van Heyningen
Journal:  Nat Genet       Date:  2001-07       Impact factor: 38.330

Review 9.  PAX6 in sensory development.

Authors:  Veronica van Heyningen; Kathleen A Williamson
Journal:  Hum Mol Genet       Date:  2002-05-15       Impact factor: 6.150

10.  Frequent chromosome aberrations revealed by molecular cytogenetic studies in patients with aniridia.

Authors:  John A Crolla; Veronica van Heyningen
Journal:  Am J Hum Genet       Date:  2002-10-17       Impact factor: 11.025

View more
  11 in total

Review 1.  Current management of wilms' tumor.

Authors:  Leah Nakamura; Michael Ritchey
Journal:  Curr Urol Rep       Date:  2010-02       Impact factor: 3.092

2.  Clinical utility gene card for: WAGR syndrome.

Authors:  Carol Clericuzio; Melanie Hingorani; John A Crolla; Veronica van Heyningen; Alain Verloes
Journal:  Eur J Hum Genet       Date:  2011-01-12       Impact factor: 4.246

3.  [Aniridia syndrome: clinical findings, problematic courses and suggestions for optimization of care ("aniridia guide")].

Authors:  B Käsmann-Kellner; B Seitz
Journal:  Ophthalmologe       Date:  2014-12       Impact factor: 1.059

Review 4.  Aniridia.

Authors:  Melanie Hingorani; Isabel Hanson; Veronica van Heyningen
Journal:  Eur J Hum Genet       Date:  2012-06-13       Impact factor: 4.246

Review 5.  [Tumor predisposition syndromes and nephroblastoma : Early diagnosis with imaging].

Authors:  N Welter; R Furtwängler; G Schneider; N Graf; J-P Schenk
Journal:  Radiologie (Heidelb)       Date:  2022-08-25

Review 6.  Pax6 3' deletion results in aniridia, autism and mental retardation.

Authors:  L K Davis; K J Meyer; D S Rudd; A L Librant; E A Epping; V C Sheffield; T H Wassink
Journal:  Hum Genet       Date:  2008-03-06       Impact factor: 4.132

Review 7.  Systemic diseases and the cornea.

Authors:  Ruchi Shah; Cynthia Amador; Kati Tormanen; Sean Ghiam; Mehrnoosh Saghizadeh; Vaithi Arumugaswami; Ashok Kumar; Andrei A Kramerov; Alexander V Ljubimov
Journal:  Exp Eye Res       Date:  2021-01-21       Impact factor: 3.467

8.  Genetic and genomic analysis of classic aniridia in Saudi Arabia.

Authors:  Arif O Khan; Mohammed A Aldahmesh; Fowzan S Alkuraya
Journal:  Mol Vis       Date:  2011-03-11       Impact factor: 2.367

9.  Improving molecular diagnosis of aniridia and WAGR syndrome using customized targeted array-based CGH.

Authors:  Fiona Blanco-Kelly; María Palomares; Elena Vallespín; Cristina Villaverde; Rubén Martín-Arenas; Camilo Vélez-Monsalve; Isabel Lorda-Sánchez; Julián Nevado; María José Trujillo-Tiebas; Pablo Lapunzina; Carmen Ayuso; Marta Corton
Journal:  PLoS One       Date:  2017-02-23       Impact factor: 3.240

Review 10.  The Challenges of Chromosome Y Analysis and the Implications for Chronic Kidney Disease.

Authors:  Kerry Anderson; Marisa Cañadas-Garre; Robyn Chambers; Alexander Peter Maxwell; Amy Jayne McKnight
Journal:  Front Genet       Date:  2019-09-04       Impact factor: 4.599

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.